Home / Market News / $MYGN
benzinga Corporate Catalyst Impact 55/100 ● positive

Craig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8

Oct 2, 2026, 5:53 PM UTC · Primary ticker $MYGN

Craig-Hallum analyst John Wilkin has reiterated a 'Buy' rating for Myriad Genetics and increased its price target from $4 to $8. This analyst action suggests a more positive outlook on the company's future performance, potentially influencing investor sentiment and the stock's short-term trading.

Craig-Hallum analyst John Wilkin maintained a 'Buy' rating on Myriad Genetics (MYGN) and significantly raised the price target from $4 to $8. This action indicates a strengthened conviction in the company's prospects, likely based on recent developments, financial performance, or market positioning. For traders, this could signal a short-term positive catalyst, potentially leading to increased buying interest and upward price movement as investors react to the upgraded outlook. The long-term implications depend on whether Myriad Genetics can meet or exceed the expectations implied by this new price target. The key opportunity for traders is to capitalize on potential short-term momentum, while the risk lies in the possibility that the market has already priced in such analyst upgrades or that the company's fundamentals do not ultimately support the higher valuation.

$MYGN positive Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.